<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713945</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/15/7826</org_study_id>
    <nct_id>NCT02713945</nct_id>
  </id_info>
  <brief_title>Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome</brief_title>
  <acronym>RASTAT</acronym>
  <official_title>Treatment With HMG-COA Reductase Inhibitor (Simvastatin) of Growth and Bone Abnormalities in Children With Noonan Syndrome: A Phase III Randomised, Double Blind, Placebo-controlled Therapeutic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase&#xD;
      inhibitors, also known as &quot;statins&quot; in the treatment of growth and skeletal abnormalities in&#xD;
      children with Noonan syndrome. Half of patients will receive simvastatin while the other half&#xD;
      will receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Noonan syndrome (NS) is a relatively frequent autosomal dominant disorder characterised by&#xD;
      facial dysmorphic features, heart defects, developmental delay, and short stature. This&#xD;
      syndrome is mostly caused by gain-of-function mutations in the PTPN11 gene, encoding tyrosine&#xD;
      phosphatase. The best-defined consequence of NS-causing mutants is an enhancement of Ras/MAPK&#xD;
      activation that is responsible for the different NS features. Mutations in several genes&#xD;
      encoding other components of the Ras/Mitogen Activated Protein Kinase (MAPK) pathway,&#xD;
      resulting in hyperactivation, are also found in syndromes close to NS.&#xD;
&#xD;
      Short stature caused by growth hormone insensitivity and skeletal abnormalities are major&#xD;
      concerns in NS. To date there is no effective specific therapy for affected patients. Given&#xD;
      the role of Ras/Mitogen Activated Protein Kinase (MAPK) activation in NS pathophysiology,&#xD;
      therapeutic strategies aiming to reduce this activation seem to be very promising.&#xD;
&#xD;
      Recently, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors, also known as&#xD;
      &quot;statins&quot; have been suggested as a potential therapy by decreasing Ras activity.&#xD;
&#xD;
      The efficacy of statins for treating cognitive deficits have been reported in mouse models of&#xD;
      NS. Statins (simvastatin) have been assessed in mouse models and clinical studies for the&#xD;
      treatment of cognitive deficits in children with discordant results but good tolerance.&#xD;
      Recently, it has been demonstrated that statins may also correct bone growth abnormality in a&#xD;
      mouse model for achondroplasia.&#xD;
&#xD;
      As growth is usually normal at birth in NS patients and thereafter progressively worsens&#xD;
      throughout childhood, the investigators expect that precocious modulation of Ras/MAPK&#xD;
      activation by statins may attenuate growth retardation. To achieve this goal, the present&#xD;
      study is the first prospective randomised placebo-controlled therapeutic trial using statins&#xD;
      in children with NS.&#xD;
&#xD;
      Marketing authorisation for statins is already accepted for the treatment of children with&#xD;
      familial hypercholesterolemia and worldwide marketing authorisation of statins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on growth in NS children as assessed by change in Insulin-like Growth Factor-1 (IGF-1) levels converted to age and sex specific z-scores</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on growth velocity as assessed by Height measurement.</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on body mass index as assessed by height and weight measurement.</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on waist circumference as assessed by clinical examination</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on hormonal growth parameters as assessed by serum IGFBP-3 levels</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on growth plates as assessed by serum C-type natriuretic peptide (CNP) levels</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on growth plates as assessed by serum amino-terminal propeptide of CNP (NTproCNP) levels</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on bone formation as assessed by serum bone alkaline phosphatase (BAP) levels</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on bone resorption as assessed by serum carboxy-terminal collagen crosslinks (CTX) levels</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on cardiac function as assessed by echocardiography</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on cognitive deficits as assessed by parent-rated child behaviour checklist (CBCL)</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on behavioural deficits as assessed by parent-rated child behaviour checklist (CBCL)</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on metabolism of lipids as assessed by lipids levels.</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on metabolism of lipids as assessed by leptin levels.</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on metabolism of lipids as assessed by adipokines levels.</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on fat body mass as assessed by Dual-energy X-ray Absorptiometry (DXA).</measure>
    <time_frame>Baseline and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on insulin sensitivity indices as assessed by Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a 12-month simvastatin treatment on insulin sensitivity indices as assessed by Quantitative Insulin-Sensitivity Check Index (QUICKI)</measure>
    <time_frame>Baseline, month 1, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Noonan Syndrome</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administrated orally once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Experimental drug administrated orally</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment for the control group</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetically confirmed Noonan syndrome&#xD;
&#xD;
          -  Female child between 6 to 15 years, without menses, with bone age &lt; 13 years&#xD;
&#xD;
          -  Male child between 6 to 16 years, with bone age &lt; 14 years&#xD;
&#xD;
          -  Decreased growth velocity (&lt; -1 SDS) and/or short stature (height &lt; -2 SDS or -1,5 SDS&#xD;
             under target height)&#xD;
&#xD;
          -  Informed consent obtained from child and parents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to simvastatin treatment :&#xD;
&#xD;
          -  Progressive liver disease, increased serum levels of alanine aminotransferase (ALT) (&gt;&#xD;
             1,5 uper limit of normal (ULN)), aspartate aminotransferase (&gt; 1,5 ULN)&#xD;
&#xD;
          -  Known hypersensitivity to simvastatin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Treatment with CYP3A4 inhibitors (erythromycin, clarithromycin, ketoconazole, or&#xD;
             itraconazole)&#xD;
&#xD;
          -  Growth promoting therapies such as recombinant human Growth Hormone (GH) or IGF-1&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Edouard, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, Toulouse University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Edouard, MD, PHD</last_name>
    <phone>+33 (0)5 34 55 85 55</phone>
    <email>edouard.t@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers Unité d'endocrinologie pédiatrique</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis COUTANT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Unité de Génétique pédiatrique</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier LACOMBE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien MOUTTON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille Unité d'endocrinologie pédiatrique</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques WEILL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Unité d'endocrinologie pédiatrique</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc NICOLINO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Marseille La Timone Unité d'Endocrinologie pédiatrique</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel REYNAUD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David GENEVIEVE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Unité de Génétique pédiatrique</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LEHEUP, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré Unité de Génétique pédiatrique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène CAVE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau Unité d'endocrinologie pédiatrique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irène NETCHINE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Unité de Génétique pédiatrique</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie ODENT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas EDOUARD, MD</last_name>
      <email>edouard.t@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Simvastatin</keyword>
  <keyword>Ras</keyword>
  <keyword>MAPK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Noonan Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

